SSC ILD PF ILD NEWSLETTER
[BI-Medical] 全身性硬化症相關之間質性肺病 (SSc-ILD) 患者接受Nintedanib治療於第100週之療效與安全性期中結果分析
患者引發腹瀉怎麼辦? 1分鐘掌握如何減緩患者不適
治療所引起肝功能異常發生率約1成,最佳處理建議這邊看!
噁心嘔吐? 快速了解如何幫助病患並給予最合適治療方針
[BI-Medical] 白血球數量對SSc-ILD病程及Nintedanib療效有影響? 一分鐘帶你快速了解
[BI-Medical] Nintedanib在PF-ILD病患的延長試驗:INBUILD-ON期中分析結果帶你看
硬皮病高峰論壇: 專家解析SSc-ILD及早診斷的重要性
監測SSc病人肺功能與HRCT,掌握病程變化及準確診斷ILD風險
[BI-Medical] ACR update:SSc-ILD 病人使用 Nintedanib 與其器官損傷之次族群分析
硬皮病高峰論壇: 3分鐘欣賞專家剖析如何運用HRCT及肺功能檢查監測SSc 病人病況變化
2023 Jan_硬皮病高峰論壇: 專家詮釋 HRCT與肺功能檢測的臨床意義
Reporting adverse events
- Patient Safety and Pharmacovigilance
Tel.: (02) 2503-2636
Fax: (02) 2503-4845
E-mail: PV_local_Taiwan@boehringer-ingelheim.com
Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.